ArticleHepatology (Baltimore, Md.)2015
Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.
Article in Hepatology (Baltimore, Md.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Breakthroughs in hepatitis C research: from discovery to cure.Nature reviews. Gastroenterology & hepatology · 2022Review
- Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.BMC health services research · 2022Article
- Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.Gastroenterology · 2019Review
- Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study.Scientific reports · 2018Observational
- Hepatitis C virus: Morphogenesis, infection and therapy.World journal of hepatology · 2018Review
- Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C.ClinicoEconomics and outcomes research : CEOR · 2018Article
- The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries.Journal of virus eradication · 2017Article
- A multifaceted computational report on the variants effect on KIR2DL3 and IFNL3 candidate gene in HCV clearance.Molecular biology reports · 2016Article
- Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial.Infectious diseases and therapy · 2016Article
- Synthesis and Structure-Activity Relationships of Imidazole-Coumarin Conjugates against Hepatitis C Virus.Molecules (Basel, Switzerland) · 2016Article
- Symptomatic Acute Hepatitis C Infection Following a Single Episode of Unprotected Sexual Intercourse.Case reports in infectious diseases · 2016Article
- Drug Pricing Evolution in Hepatitis C.PloS one · 2016Article
- Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C.Journal of virus eradication · 2016Article
- Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.Frontiers in pharmacology · 2016Article
- Development of risky varices in alcoholic cirrhosis with a well-maintained nutritional status.World journal of hepatology · 2015Article
- The extinction of chronic viral hepatitis?Clinical liver disease · 2015Review
- Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade.World journal of hepatology · 2015Review
- A public health approach to hepatitis C control in low- and middle-income countries.PLoS medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
unlabelledCombinations of direct-acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment-naïve patients. Mass treatment programs to cure HCV in developing countries are only feasible if the costs of treatment and laboratory diagnostics are very low. This analysis aimed to estimate minimum costs of DAA treatment and associated diagnostic monitoring. Clinical trials of HCV DAAs were reviewed to identify combinations with consistently high rates of sustained virological response across hepatitis C genotypes. For each DAA, molecular structures, doses, treatment duration, and components of retrosynthesis were used to estimate costs of large-scale, generic production. Manufacturing costs per gram of DAA were based upon treating at least 5 million patients per year and a 40% margin for formulation. Costs of diagnostic support were estimated based on published minimum prices of genotyping, HCV antigen tests plus full blood count/clinical chemistry tests. Predicted minimum costs for 12-week courses of combination DAAs with the most consistent efficacy results were: US$122 per person for sofosbuvir+daclatasvir; US$152 for sofosbuvir+ribavirin; US$192 for sofosbuvir+ledipasvir; and US$115 for MK-8742+MK-5172. Diagnostic testing costs were estimated at US$90 for genotyping US$34 for two HCV antigen tests and US$22 for two full blood count/clinical chemistry tests.
conclusionsMinimum costs of treatment and diagnostics to cure hepatitis C virus infection were estimated at US$171-360 per person without genotyping or US$261-450 per person with genotyping. These cost estimates assume that existing large-scale treatment programs can be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.